Atul Pande Sells 6,000 Shares of Immunovant (NASDAQ:IMVT) Stock

Immunovant, Inc. (NASDAQ:IMVT) Director Atul Pande sold 6,000 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $32.00, for a total transaction of $192,000.00. Following the completion of the sale, the director owned 116,731 shares in the company, valued at approximately $3,735,392. The trade was a 4.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunovant Stock Down 4.0%

IMVT stock opened at $34.13 on Friday. Immunovant, Inc. has a twelve month low of $13.79 and a twelve month high of $36.28. The company has a market cap of $6.95 billion, a PE ratio of -12.28 and a beta of 0.70. The business’s 50-day simple moving average is $26.65 and its 200 day simple moving average is $25.85.

Immunovant (NASDAQ:IMVT) last issued its earnings results on Wednesday, May 20th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.13). During the same quarter last year, the business posted ($0.64) earnings per share. On average, equities research analysts anticipate that Immunovant, Inc. will post -2.6 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Immunovant by 8.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,971 shares of the company’s stock worth $708,000 after purchasing an additional 3,348 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Immunovant by 48.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,007,700 shares of the company’s stock worth $17,222,000 after buying an additional 329,354 shares during the last quarter. Strs Ohio bought a new stake in Immunovant during the first quarter worth $27,000. Legal & General Group Plc raised its position in Immunovant by 6.9% during the second quarter. Legal & General Group Plc now owns 77,296 shares of the company’s stock worth $1,237,000 after acquiring an additional 5,010 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in Immunovant by 20.7% in the second quarter. Invesco Ltd. now owns 66,750 shares of the company’s stock valued at $1,068,000 after acquiring an additional 11,438 shares during the last quarter. 47.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Sanford C. Bernstein began coverage on shares of Immunovant in a research report on Friday, March 20th. They set a “market perform” rating and a $28.00 target price for the company. The Goldman Sachs Group raised their price target on Immunovant from $29.00 to $32.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Bank of America lifted their target price on shares of Immunovant from $32.00 to $43.00 and gave the stock a “buy” rating in a report on Thursday. Guggenheim upped their price target on Immunovant from $41.00 to $44.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunovant in a research note on Wednesday, April 8th. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Immunovant currently has a consensus rating of “Hold” and an average price target of $34.44.

Immunovant News Summary

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: Immunovant reported strong Phase 2 rheumatoid arthritis data for IMVT-1402, with ACR20/50/70 response rates of 72.7%, 54.5%, and 35.8%, respectively, fueling optimism about the drug’s efficacy. Article Title
• Positive Sentiment: Roivant-backed coverage highlighted the results as a validation of the broader investment case, suggesting the clinical win could support value creation across Immunovant’s autoimmune pipeline. Article Title
• Positive Sentiment: Management also said the cutaneous lupus proof-of-concept trial is fully enrolled, with topline data expected in the second half of 2026, giving investors another potential catalyst. Article Title
• Positive Sentiment: The company reported a strong cash position of about $902 million as of March 31, which should help fund development and extend runway toward a possible future launch. Article Title
• Neutral Sentiment: The quarterly loss was wider than expected, with EPS of -$0.73 versus estimates for -$0.60, but investors appear to be focusing more on the clinical readout than the earnings miss. Article Title
• Negative Sentiment: Director Atul Pande sold 6,000 shares in a pre-arranged Rule 10b5-1 transaction, which may slightly weigh on sentiment even though the sale was planned in advance. Article Title

About Immunovant

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.